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Abstract
Background: To compare luteal phase bleeding and pregnancy outcomes in normogonadotropic patients
receiving progesterone vaginal gel (PVG) or intramuscular progesterone (IMP) injections.
Methods: In this retrospective cohort study, data from 270 patients (292 cycles) undergoing day-3 fresh
embryo transfer were analyzed. PVG, 90 mg daily (170 cycles) or IMP, 50 mg daily (122 cycles) began at
egg retrieval.
Results: Luteal phase bleeding was significantly more common in the PVG than the IMP group. No signif-
icant differences were observed in biochemical pregnancy or spontaneous abortion rates between the two
groups. Patients who bled before the pregnancy test had significantly lower total and clinical pregnancy rates
than non-bleeders. Total and ongoing pregnancy/delivery rates were higher in the PVG than IMP group, but
did not achieve statistical significance.
Conclusion: Luteal phase bleeding was more common in the PVG group than the IMP group, but pregnancy
was successful in more patients in the PVG group. Luteal phase bleeding is prevented or delayed during IMP
treatment, but patients who bled before the pregnancy test, whether using the gel or injected progesterone,
had significantly reduced pregnancy rates compared with non-bleeders.
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Introduction
Progesterone has been traditionally used for luteal support
in cycles of assisted reproduction. In addition to oral,
intramuscular, and vaginal suppository formulations, a
vaginal gel of micronized progesterone (Crinone® 8%,
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nColumbia Research Laboratories, Livingston, NJ) is avail-
able. This is micronized progesterone contained in a pol-
ycarbophil-based gel, which is designed to provide a con-
trolled and sustained release of the hormone over a 48- to
72-hour interval after a single vaginal application [1,2].
Several randomized prospective trials and non-random-
ized prospective studies compared micronized progester-
one vaginal gel (PVG) with intramuscular progesterone
(IMP; progesterone in oil) in cycles of assisted reproduc-
tive technology (ART) [3–9]. Many of these studies noted
no significant difference in clinical pregnancy rates, but
reported a higher incidence of biochemical pregnancy
rates and lower implantation rates with PVG compared
with IMP. However, Abate et al. reported significantly
higher ongoing pregnancy rates with IMP [4]. An interim
analysis of a prospective, randomized trial, published in
2001, reported lower clinical pregnancy and live birth
rates in PVG versus IMP ART cycles in which treatment
with both progesterone products started 24 hours after
oocyte retrieval [8]. Recently, the same group published
interim outcomes from a subsequent prospective, random-
ized trial comparing both products; however, PVG was
started 48 hours after oocyte retrieval while IMP treatment
was started 24 hours after oocyte retrieval [9]. The ration-
ale for the later start time with PVG was based on the
product’s greater bioavailability versus IMP [1,10].
In our ART practice, PVG gained prompt acceptance with
patients. However, in a number of cases, patients experi-
enced luteal phase bleeding prior to the pregnancy test.
Bleeding during the luteal phase of ART cycles and prior
to the pregnancy test generates concern and distress for
patients because they fear that the bleeding is a sign of
treatment failure. Bleeding patterns were a measured out-
come in several previous studies. Jobanputra et al. repor-
ted that only one of 44 patients using PVG bled before the
pregnancy test but, nonetheless, delivered twins at term
[5]. A greater proportion of PVG patients (27% IMP vs
42% PVG; P = 0.02) reported bleeding prior to the preg-
nancy test in the study by Yanushpolsky et al. but implan-
tation and ongoing pregnancy rates were similar in both
groups [9]. Roman et al. studied vaginal bleeding in
women undergoing in vitro fertilization (IVF)/intracyto-
plasmic sperm injection (ICSI) and observed no shortened
luteal phase when using vaginal micronized progesterone
(200 mg three times a day [t.i.d.]) in soft gelatin capsules
(Piette Pharmaceuticals, Brussels, Belgium) [11]. In 100
patients treated with IMP who did not become pregnant
following ART, 67 reported bleeding within 17 days fol-
lowing oocyte retrieval [12].
Since there are few systematic studies addressing the issue
of luteal phase bleeding with PVG or IMP as progesterone
supplementation in ART cycles, we designed the current
study with two objectives: (1) to compare the incidence
and the onset of luteal phase bleeding after embryo trans-
fer (ET) and prior to the serum pregnancy test; and (2) to
compare the pregnancy outcomes between the two treat-
ment groups and between patients who experienced luteal
phase bleeding versus those who did not.
Material and Methods
Patient Population
Outcomes from 270 patients, with a total of 292 cycles,
were analyzed. All patients were treated at the University
of Pennsylvania Medical Center during 1999 and January
through June 2000, were less than 40 years of age and
underwent a fresh ET cycle. Patients undergoing egg don-
ation cycles were excluded from this analysis. The PVG
group (n = 159 patients, 170 cycles) received 90 mg daily
(Crinone® 8%) administered vaginally, while the IMP
group (n = 111 patients, 122 cycles) received progesterone
in oil, 50 mg daily, via intramuscular injection.
The protocol of ovarian stimulation was similar between
groups, consisting of gonadotropin-releasing hormone
agonist (GnRH-a) down-regulation with leuprolide ace-
tate (0.5 mg, Lupron®, TAP Pharmaceuticals Products,
Lake Forest, IL) commenced in the mid-luteal phase, fol-
lowed by split doses of recombinant human follicle-stim-
ulating hormone (r-hFSH; GONAL-f®, EMD Serono,
Inc., Rockland, MA), and reduction of GnRH-a to 0.25 mg
with the initiation of r-hFSH treatment. Ovarian stimula-
tion was managed by two physicians only and adjusted
depending on follicular response, as assessed by ultra-
sound monitoring and estradiol (E2) levels. When 3–4 fol-
licles with a mean diameter of 20 mm or more were seen
on ultrasound, human chorionic gonadotropin (hCG)
(10,000 IU intramuscularly) was administered, followed
by oocyte retrieval 36 hours later. ET was scheduled to
occur 3 days following oocyte retrieval. For each patient,
2–4 embryos were transferred depending on the age of the
patient and the quality of available embryos. In both
groups, progesterone supplementation was initiated on the
evening of egg retrieval.
Analysis
This study was analyzed as a retrospective cohort study.
Primary outcomes were the presence of early vaginal
bleeding and pregnancy. An ongoing pregnancy was
defined by the presence of a fetal heartbeat or a known,
delivered infant after 20 weeks of gestation. For the pur-
poses of this study, implantation rate was defined as the
ratio of the number of gestational sacs on ultrasound divi-
ded by the total number of embryos transferred. Sponta-
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nneous abortion was defined as the loss of an ongoing preg-
nancy before 20 weeks of gestation. Biochemical preg-
nancy was defined as a positive β-hCG (> 5 mLU/mL) in
a patient who failed to demonstrate a pregnancy by ultra-
sound. Luteal phase bleeding was defined as any bleeding
or spotting reported to the office prior to the scheduled
pregnancy test (day 14 after ET). This information was
collected by the nursing staff and entered on a dated
phone-consultation sheet.
Direct comparisons of selected variables between the two
groups were performed using Student’s t-test, Chi-square
test, or Fisher’s exact test where appropriate. All tests were
two-sided and P < 0.05 was considered significant. Asso-
ciations between outcomes and the progesterone treatment
groups were assessed using both relative risks and odds
ratios (ORs). As these measures gave similar results, the
ORs are reported and were included in the subsequent
multivariable logistic regression models.
To identify potential confounding variables and possible
modifiers of the association between progesterone formu-
lations and outcome (i.e. interactions between progester-
one group and other variables), both unadjusted and strati-
fied analyses were performed. Multivariable logistic
regression was then used to estimate the OR for outcome
(pregnancy) adjusted for all potential confounders. Vari-
ables were included in the logistic regression model if (a)
they were biologically plausible, (b) they demonstrated P
< 0.20 for the association with outcome in the unadjusted
analyses, or (c) adjustment for the given variable changed
the OR for PVG versus IMP by 10% [13,14]. The factors
included in the final model were age (continuous variable)
and etiology of infertility (categorical variable). Day-3
FSH serum concentration, starting dose of gonadotropin,
number of oocytes retrieved, and the use of ICSI were not
found to be confounders in the analysis and were not
included in the final model.
Results
Both groups were similar for day-3 FSH, etiology of infer-
tility, gonadotropin dose, days of stimulation, number of
follicles, E2 levels, number of eggs retrieved, use of ICSI,
and endometrial stripe thickness on the day of hCG admin-
istration (Table 1).
The percentage of cycles with bleeding before the preg-
nancy test was significantly higher in the PVG group than
the IMP group (37.1%, n = 63/170 vs 7.4% n = 9/122, P
< 0.0001). Furthermore, for the patients who experienced
luteal phase bleeding, the onset of bleeding occurred one
day earlier in the PVG group (8.5 vs 9.5 days after ET),
but this difference was not statistically significant (P =
0.09) (Table 2).
Total and ongoing pregnancy rates were higher in the PVG
group than in the IMP group, although the difference did
not reach statistical significance (52.3% vs 43.4%, P =
0.07 and 41.2% vs 33.6%, P = 0.08, respectively). The
Table 1.
Clinical characteristics in ART cycles treated with progesterone vaginal gel (PVG) versus intramuscular progesterone
(IMP)
Variable
  PVG group
  IMP group
  P value
 
Number of patients (cycles) 159 (170) 111 (122)
Mean ± SD age, years 33.1 ± 4.7 34.4 ± 3.5 0.004*
Mean ± SD day-3 FSH, mLU/mL 7.0 ± 2.1 7.0 ± 2.1 0.87*
Etiology of infertility 0.16†
  Unexplained, % 23.5 19.7
  Endometriosis, % 17.7 18.8
  Tubal, % 21.7 33.6
  Male, % 29.4 17.2
  PCO/anovulation, % 4.1 4.9
  Pelvic adhesions, % 1.1 0.8
  Uterine, % 0.6 0.8
  Other, % 1.8 4.1
Mean ± SD number of follicles 19.7 ± 7.5 18.8 ± 11.9 0.50*
Mean ± SD number of eggs retrieved 13.8 ± 5.6 11.5 ± 5.8 0.08*
ICSI, % 21.8 16.3 0.25†
Mean ± SD E2 level on day of hCG
administration, pg/mL
3577 ± 1453 3316 ± 1565 0.14*
Mean ± SD ES thickness on day of
hCG administration, mm
11.5 ± 2.3 12.1 ± 2.6 0.06*
Fertilization rate, %
  54
  55
  0.85†
 
E2 = estradiol; ES = endometrial stripe; FSH = follicle-stimulating hormone; hCG = human chorionic gonadotropin; ICSI = intracytoplasmic sperm injection;
PCO = polycystic ovary/ovaries; SD = standard deviation.
*
Student’s t-test;
†
Chi-square test.
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nimplantation rates, biochemical pregnancy rates, and
spontaneous abortion rates were similar in both groups
(24.0% vs 18.7%, P = 0.09; 14.6% vs 11.3%, P = 0.78,
and 6.7% vs 5.7%, P = 0.77 in the PVG vs IMP groups,
respectively).
Despite comparable E2 levels (3291 ± 208 pg/mL vs 3485
± 121 pg/mL, P = 0.41), patients from both groups who
bled prior to pregnancy testing had a significantly thicker
endometrial stripe on the day of hCG administration (12.6
± 2.9 mm vs 11.6 ± 2.3 mm, P = 0.004), when compared
with the non-bleeders (Table 3). As a whole, cycles with
luteal phase bleeding before the pregnancy test, whether
using PVG or IMP, had significantly reduced total and
clinical pregnancy rates compared with those without
bleeding (19.4% vs 58.2%, P < 0.001 and 9.7% vs 47.3%,
P < 0.001 respectively). The total pregnancy rate among
cycles with luteal phase bleeding in the PVG group was
22.2% (14/63) while the ongoing pregnancy rate was
11.1% (7/63). None of the patients who bled early in the
IMP group were pregnant (0/9) (Table 4).
Table 2.
Luteal phase bleeding and pregnancy outcomes in ART cycles treated with progesterone vaginal gel (PVG) versus
intramuscular progesterone (IMP)
  PVG group
  IMP group
  Odds ratio (crude)
  P-value (crude)
 
Odds ratio (adjus-
ted)
 
P value (adjusted)
 
Number of patients
(cycles)
159 (170) 111 (122) – – – –
Bleeding before day
14
63/170 (37.1%) 9/122 (7.4%) 6.59 (3.2–13.52) < 0.001* 6.25 (3.0–13.01) < 0.0001*
Mean day of bleed-
ing after hCG
8.5 9.5 – – 0.09†
Implantation rates 24.0% 18.7% 1.80 (0.81–3.99) 0.15 2.09 (0.89–4.91) 0.09*
Total pregnancies 89/170 (52.3%) 53/122 (43.4%) 1.43 (0.9–2.28) 0.13 1.58 (0.96–2.61) 0.07*
Ongoing pregnan-
cies
70/170 (41.2%) 41/122 (33.6%)‡ 1.38 (0.85–2.24) 0.19 1.60 (0.95–2.69) 0.08*
Biochemical preg-
nancies
13/89 (14.6%) 6/53 (11.3%) 1.34 (0.48–3.77) 0.58 1.17 (0.39–3.52) 0.78*
Spontaneous abor-
tions
 
6/89 (6.7%)
  3/53 (5.7%)
  1.20 (0.29–5.03)
  0.80
  1.25 (0.27–5.71)
  0.77*
 
*
Chi-square test;
†
Student’s t-test;
‡
Three patients with positive pregnancy tests were subsequently lost to follow-up.
Table 3.
Endometrial stripe thickness (ES) and estradiol levels (E2) in ART cycles with luteal phase bleeding versus non-
bleeding
  Luteal phase bleeding
  Non-bleeding
  P value
 
Number of cycles 72 220 –
Mean ± SD E2 on day of hCG admin-
istration, pg/ml
3291 ± 208 3485 ± 121 0.41*
Mean ± SD ES thickness on day of
hCG administration, mm
12.6 ± 2.9 11.6 ± 2.3 0.004*
Total pregnancies (%) 14/72 (19.4) 128/220 (58.2) 0.001†
Ongoing pregnancies (%)
  7/72 (9.7)
  104/220 (47.3)
  < 0.001†
 
SD = standard deviation; hCG = human chorionic gonadotropin.
*
Student’s t-test;
†
Chi-square test.
Table 4.
Pregnancy rates* in cycles with luteal phase bleeding using progesterone vaginal gel (PVG) or intramuscular proges-
terone (IMP)
  n
  Total pregnancy rate*
  Ongoing pregnancy rate*
 
All patients with luteal phase bleed-
ing, n (%)
72 14 (19.4) 7 (9.7)
  PVG group, n (%) 63 14 (22.2) 7 (11.1)
  IMP group, n (%)
  9
  0 (0)
  0 (0)
 
*
Number of pregnancies and percentage of total pregnancies.
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nDiscussion
Progesterone supplementation during the luteal phase has
been considered standard treatment in most ART centers
[15]. Despite various formulations and routes of admin-
istration available, the use of IMP is still the dominant
choice in the United States. The major disadvantage of
IMP is the discomfort associated with intramuscular injec-
tions, in addition to the potential risks for local inflam-
matory reactions and abscesses that could arise from
repetitive injections of the oil vehicle [7]. The formulation
of progesterone as a vaginal gel, from a practical perspec-
tive, is very convenient and well tolerated by patients with
few side-effects. However, luteal phase bleeding prior to
the scheduled pregnancy test generates significant anxi-
ety. This occurrence coupled with questions of decreased
pregnancy rates in cycles using this form of luteal pro-
gesterone supplementation prompted us to review our own
extensive experience.
The data collected in the present study confirm the impres-
sion that patients receiving PVG for luteal support in fresh
ET cycles were more likely to bleed prior to their preg-
nancy test than those treated with IMP. However, an inter-
esting finding from the analysis is that neither pregnancy
nor implantation rates significantly differed between the
two treatment groups. In fact, our data show that most of
the patients who experienced luteal phase bleeding (in
both PVG and IMP groups) were either not pregnant or
did not achieve an ongoing pregnancy. Thus, it seems that
early bleeding was unrelated to implantation failure or
pregnancy loss [16].
In some ART clinics, high E2 levels (>3200 pg/mL)
observed on the day of hCG administration may indicate
ovarian hyperstimulation. However, none of the patients
with elevated E2 levels developed ovarian hyperstimula-
tion syndrome in this study. Moreover, there was no sig-
nificant difference between the IMP and PVG groups in
terms of the mean E2 levels on the day of hCG adminis-
tration (Table 1), nor was a significant difference observed
in patients with and without luteal phase bleeding (Table
3). While the E2 levels observed in our program may be
indicative of hyperstimulation in some ART clinics, the
explanation may lie in variability of E2 assays between
laboratories.
An intriguing, but certainly not surprising, finding of the
present study was the observation that cycles with luteal
phase bleeding had a significantly thicker endometrial
stripe on the day of hCG administration compared with
the non-bleeders (12.6 mm vs 11.6 mm, P = 0.004). Based
on this finding, a subgroup of patients may benefit from
increased progesterone supplementation based on the
endometrial thickness measurement on the day of hCG
administration. The data from the present study do not
support either hypothesis, but point to the need for addi-
tional investigations.
First-trimester bleeding in spontaneous pregnancies is not
uncommon, occurring about 20% of the time [17]. Fol-
lowing ART, the reported incidence of first-trimester
bleeding is higher, ranging from 29% to 36% [18,19]. As
noted previously, luteal phase bleeding was not a meas-
ured outcome in the majority of previous comparative
studies between PVG and IMP. Roman et al. addressed
the issue of bleeding during the luteal phase of IVF/ICSI
cycles, yet the authors reported no shortened luteal phase
[11]. In that study, however, vaginal gelatin capsules of
micronized progesterone (at a dose of 200 mg t.i.d.)
instead of PVG were utilized, and there was no IMP con-
trol group. Yanushpolsky et al. reported the results of an
interim analysis from a prospective, randomized study
comparing the efficacy and tolerability of PVG and IMP
for luteal phase support in ART [9]. Although a signifi-
cantly higher proportion of patients receiving PVG than
IMG reported bleeding before the first pregnancy test
(42% vs 27%, respectively; P = 0.02), similar implanta-
tion, pregnancy, and spontaneous abortion rates were
found in the two treatment groups.
Of greater concern to patients and medical staff alike has
been the suggestion that luteal phase support with PVG
may compromise implantation and pregnancy rates. Con-
flicting results have been reported in the literature regard-
ing this issue. Several prospective studies have demon-
strated that PVG is as effective as IMP for luteal phase
supplementation in ART cycles [3,5–7]. However, one
randomized, controlled (open label) study noted that PVG
resulted in significantly lower embryo implantation, clin-
ical pregnancy, and live birth rates compared with the
pregnancy outcomes in women supplemented with IMP
[8]. Nonetheless, this study might have been limited by
type I error and bias despite its randomized design [20],
and a subsequent study from the same group showed no
differences in treatment outcomes [9]. Others have repor-
ted significantly higher implantation and clinical preg-
nancy rates with PVG compared with IMP in ICSI but not
classic IVF cycles. These observations suggest that the
differences may be attributed to a direct effect of proges-
terone on the oocyte, which is deprived of progesterone
due to decoronization prior to sperm injection. Because
progesterone levels are significantly higher in the local
environment after PVG administration, a possible ‘rescue
effect’ of progesterone on both the early embryo and
endometrium may occur in ICSI cycles [21].
Several limitations may be noted regarding this study. For
the purpose of our analysis, the number of embryos trans-
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nferred and multiple pregnancy rates were inadvertently
excluded when data were extracted from the patients’
charts. However, the overall data from our center were
published in the Assisted Reproductive Technology Suc-
cess Rates National Summary and Fertility Clinic
Reports for the time periods during which these patients
were treated [22,23]. The mean number of fresh embryos
transferred ranged from 2.5 for patients aged under 35
years to 3.3 for those aged 38–40 years. The percentage
of twin pregnancies ranged from 25% for patients aged
under 35 years to 40% for those aged 35–37 years. The
percentage of triplet pregnancies ranged from 0% for
patients aged under 35 years to 15.4% for those aged 35–
37 years.
An important observation relevant to clinical practice is
confirmation of the effectiveness of PVG for luteal sup-
port and the observation that, contrary to other reports,
biochemical pregnancy rates were similar to patients in
the IMP group [5,6]. In addition, it should be noted that a
trend towards higher implantation and pregnancy rates
was also observed in the PVG users (Table 2). However,
this observation may be explained by the fact that patients
in the PVG group were significantly younger than those
in the IMP group.
In conclusion, the results of this study suggest that patients
using PVG should be informed that they might experience
vaginal spotting prior to their pregnancy test, but they
should be reassured that this bleeding does not indicate
treatment failure nor does it affect their chances of ach-
ieving a pregnancy. They should be counseled that even
if they bleed early on, they should continue taking PVG
until the pregnancy test (12–14 days after the ET). A pro-
spective, randomized trial of sufficient statistical power is
needed to confirm these data and to further evaluate the
relationship between endometrial stripe thickness and
early vaginal bleeding.
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